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Abstract
Background: A recent analysis of protein sequences deposited in the NCBI RefSeq database indicates that ~8.5
million protein sequences are encoded in prokaryotic and eukaryotic genomes, where ~30% are explicitly
annotated as “hypothetical” or “uncharacterized” protein. Our Comparison of Protein Active-Site Structures (CPASS
v.2) database and software compares the sequence and structural characteristics of experimentally determined
ligand binding sites to infer a functional relationship in the absence of global sequence or structure similarity.
CPASS is an important component of our Functional Annotation Screening Technology by NMR (FAST-NMR)
protocol and has been successfully applied to aid the annotation of a number of proteins of unknown function.
Findings: We report a major upgrade to our CPASS software and database that significantly improves its broad
utility. CPASS v.2 is designed with a layered architecture to increase flexibility and portability that also enables job
distribution over the Open Science Grid (OSG) to increase speed. Similarly, the CPASS interface was enhanced to
provide more user flexibility in submitting a CPASS query. CPASS v.2 now allows for both automatic and manual
definition of ligand-binding sites and permits pair-wise, one versus all, one versus list, or list versus list comparisons.
Solvent accessible surface area, ligand root-mean square difference, and Cb distances have been incorporated into
the CPASS similarity function to improve the quality of the results. The CPASS database has also been updated.
Conclusions: CPASS v.2 is more than an order of magnitude faster than the original implementation, and allows
for multiple simultaneous job submissions. Similarly, the CPASS database of ligand-defined binding sites has
increased in size by ~ 38%, dramatically increasing the likelihood of a positive search result. The modification to
the CPASS similarity function is effective in reducing CPASS similarity scores for false positives by ~30%, while
leaving true positives unaffected. Importantly, receiver operating characteristics (ROC) curves demonstrate the high
correlation between CPASS similarity scores and an accurate functional assignment. As indicated by distribution
curves, scores ≥ 30% infer a functional similarity. Software URL: http://cpass.unl.edu.
Background
The Comparison of Protein Active-Site Structures
(CPASS) [1] is an integral component of our FAST-
NMR methodology [2,3] to annotate proteins of
unknown function. CPASS is based on the premise that
ligand-binding sites or functional epitopes are more
evolutionary stable relative to the remainder of the pro-
tein [4,5]. Thus, a protein of unknown function is anno-
tated by identifying proteins of known function that
share similar ligand-binding sites [6]. The FAST-NMR
and CPASS methodology is well-suited to situations
where global sequence or structure similarity has failed
to assign a function [7]. CPASS has contributed to a
functional hypothesis for the Staphylococcus aureus pro-
tein SAV1430 [3], Pseudomonas aeruginosa protein
PA1324 [8], Pyrococcus horikoshii OT3 protein PH1320
[2], and human protein Q13206 [2]. The basic CPASS
approach has been used to provide an annotation to the
Bacillus subtilis protein YndB [9]. Also, CPASS was
used to identify a functional relationship between the
bacterial type III secretion system and eukaryotic apop-
tosis [10].
CPASS compares the sequence and structural charac-
teristics between experimental ligand-defined active-sites
or functional epitopes to identify a functional relation-
ship. This is uniquely different from other bioinformatic
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any medium, provided the original work is properly cited.tools such as eF-seek [11], PINTS [12,13], ProFunc [14],
and many others [15] that attempt to predict the loca-
tion of ligand-binding sites based on structural features
such as spatially conserved residues, surface pockets, or
other physiochemical properties. Programs such as
@TOME-2 [16], 3DLigandSite [17], and firestar [18]
predict ligand binding sites or functional similarity
through the global alignment of protein structures,
where reference structures contain bound ligands. Con-
versely, ProteMiner-SSM [19], Query3d [20], and Site-
Base [21] are similar in concept to CPASS, where only
ligand-binding site substructures are used as a database
query. CPASS uses the entire binding site defined from
a direct interaction with a ligand, where any amino-acid
that is within 6 Å of the bound ligand comprises the
ligand-defined binding site. Thus, CPASS uses a com-
prehensive database comprised of every distinct ligand-
binding site present in the RCSB Protein Data Bank
(PDB) [22]. The presence of a different ligand, a global
sequence similarity less than 90%, or an active site simi-
larity less than 80% correlates with a unique binding site
in the CPASS database. As a result, a CPASS search is
extremely exhaustive, but time consuming. Conversely,
other software that attempt to predict the location of a
ligand-binding site typically use reduced definitions of
known ligand binding sites, such as a triad of highly
conserved residues. These approaches are optimized for
speed, but generally identify numerous ambiguous
ligand binding sites.
We report here a major upgrade to our CPASS soft-
ware and database that significantly improves the broad
utility of CPASS. The enhancements include more than
an order of magnitude reduction in the time required to
completely search the CPASS database, an approximate
38% increase in the size of the CPASS database of ligand
binding sites, the incorporation of additional terms in
our active-site similarity function that further differenti-
ates true positives from false positives, and improve-
ments in the CPASS user interface.
Methods
Prior CPASS implementation
As described in an earlier work [23], the CPASS suite
previously utilized a 16-node Beowulf Linux cluster to
both store the database and perform the computations.
The various components of the suite (user interface
(UI), preprocessing, computation, database, post proces-
sing) were tightly integrated, as well as non-portable.
Additionally, the design was such that only one compar-
ison sweep could be performed at a time, with no
mechanism to queue jobs. This model served the pur-
pose during the initial development, but had several
inherent limitations for a larger user base.
The non-portable nature of the code (e.g. hard-coded
file paths) meant that CPASS was not scalable beyond
the original 16-node cluster. The single-user nature and
lengthy computation time for a full comparison (~1 day)
resulted in severely limited computational throughput.
The tight integration of the components also limited
flexibility for modification; a change in one area could
require altering other components. Finally, there were
no mechanisms for fault-tolerance in place. For exam-
ple, a failure of one compute node, or in one layer of
the application stack, could require the comparison to
be begun again. Thus, there were several well-defined
areas in which improvements could be made.
Current CPASS implementation
The current CPASS design directly addresses the issues
described above. In order to allow scaling beyond the
original cluster, all components were modified to be
portable. Additionally, the previous tight integration
has been replaced with a layered architecture (Figure
1). These consist of distinct UI, Computation, and
Data layers, discussed below. The primary advantage of
this approach is flexibility; each layer operates asyn-
chronously, and may be modified independent of the
others. Communication between the UI and Computa-
tion layers is file-based, with checkpoints present in
the workflow. A degree of fault-tolerance is thus intro-
duced; if either layer fails, loss is limited to a single
layer, and the workflow can be resumed from the last
checkpoint.
The UI layer runs on a single server, and is responsi-
ble for the user-facing web portal, pre-processing of the
user-supplied data, and display of the results. When a
user submits a CPASS comparison through the portal,
the UI layer performs the pre-processing and logs the
job details. Periodically, the logs are scanned for pend-
ing jobs, which are then sent to the Computation layer
and logged as active. The Computation layer is moni-
tored for job status, and upon completion, post-proces-
sing and logging are performed. The UI layer parses the
log files, as well as directly querying the Computation
layer, on demand from the user. If the job is complete,
the results may be displayed. In the prior CPASS imple-
mentation, each individual comparison generated results
as static html documents. Result pages are now gener-
ated dynamically from plain-text files produced at the
Computation layer. Additionally, the current architec-
ture allows multiple concurrent users. Upon submission,
each comparison is assigned a unique working directory
where all related data is kept. This allows multiple users
to submit an arbitrary number of jobs, which are
then queued at the Computation layer in the order they
are received.
Powers et al. BMC Research Notes 2011, 4:17
http://www.biomedcentral.com/1756-0500/4/17
Page 2 of 15The Computation layer is responsible for executing
the core CPASS functionality. A full CPASS sweep is
broken into a cluster of several hundred independent
jobs prior to submission to the Condor batch system
[24,25], which is used in conjunction with glideinWMS
[26]. Condor is a specialized workload management sys-
t e md e s i g n e df o rh i g h - t h r o u g h p u tc o m p u t i n g .I ti s
responsible for job queuing, scheduling, prioritization,
resource monitoring, and resource management. The
glideinWMS mechanism simplifies utilization of the
hundreds of independent sites that form the Open
Science Grid [27] (OSG). The combination of the two
provides a scalable architecture for opportunistic use of
Grid compute resources.
A Condor instance is run on the same server the UI
layer resides on. The cluster of jobs is submitted to the
local Condor instance, which is then distributed using
glideinWMS to available Grid compute nodes for execu-
tion. Each job is responsible for comparison against a
subset of the complete database. Upon completion of
each job, the results are transferred back to its local
working directory to be displayed by the UI layer. Utiliz-
ing the Condor scheduler also provides tolerance against
job failure. As each individual job in the cluster is inde-
pendent, any number may fail at any time without
affecting the rest. Condor will detect the failure, and
reschedule the job for execution at a different location.
With this implementation jobs are run at disparate sites,
thus a shared file system is no longer present. Conse-
quently, the relevant database files must be distributed
to the remote worker nodes, necessitating the addition
of the Data layer.
The Data layer’sr o l ei st oh o s tt h eC P A S Sd a t a b a s e ,
and serve the required files to individual jobs on
demand. Given that the database itself consists of a
large number of relatively small (approximately 1 MB)
files, http-based distribution was chosen. The Data
layer consists of a Linux Virtual Server [28] (LVS)
Figure 1 Illustration of the three distinct layers in the current CPASS implementation. The User Interface (UI) Layer processes user
requests and displays results. The Computation Layer deploys jobs over the internet to remote Open Science Grid (OSG) worker nodes, and
collects the results. The Data Layer provides necessary database files to both the UI and Computation Layers.
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tion. The LVS is a scalable, high availability (HA) server
composed of a cluster of real servers with a Linux-based
load balancer. Currently this consists of the required
two load balancers (a primary and a backup), and two
Apache web servers. As CPASS usage grows, this will
place increasing demands on the Data layer to deliver
f i l e s .T h es c a l a b l en a t u r eo fa nL V Sm e a n st h a ta d d i -
tional web servers may be added transparently to cope
with increased demand. Additionally, the HA feature is
such that one load balancer, and all but one web server,
may fail without interruption to the overall LVS. The
Computation layer can continue to operate, although
possibly at a reduced level of performance depending on
demand.
The current CPASS implementation addresses several
core issues identified previously, with significant
improvements in flexibility, scalability, and fault-toler-
ance. Separation of the architecture into distinct layers
allows for ease of development. Portability and scalabil-
ity ensures that as demand grows, additional resources
may be utilized more easily. The addition of fault-toler-
ance in all levels aims to improve the user experience.
Most importantly, the ability for high computational
throughput will greatly enhance the value of CPASS as
an analysis tool.
CPASS similarity function
The original CPASS similarity function was based on a
Ca distance-weighted BLOSUM62 [29,30] probability
function.
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where active site a contains n residues and is com-
pared to active site b from the CPASS database which
contains m residues, pi,j is the BLOSUM62 probability
for amino-acid replacement for residue i from active site
a with residue j from active site b, ΔRMSDi,j is a cor-
rected root-mean square difference in the Ca coordinate
positions between residues i and j,a n ddmin/di is the
ratio of the shortest distance to the ligand among all
amino-acids in the active site compared to the current
amino-acid’s shortest distance to the ligand.
The upgraded version of CPASS has incorporated
three changes into the similarity function. These
changes correspond to the inclusion of the solvent
accessible surface area of the aligned residues, the root-
mean square difference (RMSD) between the two bound
ligands, and the addition of the Cb position in the dis-
tance calculation (ΔRMSDi,j). For residue alignments
that involve at least one glycine residue, the per residue
distance calculation only uses Ca coordinate positions
between residues i and j.
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where ΔRMSDlig is a corrected root-mean square dif-
ference between the ligands that define the two binding
sites and ΔSASAi,j is the difference in the solvent acces-
sible surface area (SASA) between residues i and j.T h e
penalty functions for the RMSD between the two
ligands, the per residue Ca-Cb position in the distance
Figure 2 Graphical representations of the penalty functions for
(A) ligand root-mean square difference (RMSD), (B) per residue
RMSD in Ca and Cb positions, and (C) solvent accessible
surface area (SASA) differences in the CPASS similarity score.
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aligned residues are illustrated in figure 2.
The solvent accessible surface area for each residue in
each structure is calculated using the program NAC-
CESS [31]. Specifically, the relative all atom solvent
accessible surface area is used. All heteroatoms in the
PDB are ignored in the NACCESS calculation, so the
solvent accessible surface area corresponds to a ligand-
free structure. For structures that contain bound pep-
tides or nucleotides, the peptides or nucleotides were
removed from the PDB prior to the NACCESS
calculation.
The RMSD between the two ligands is calculated by
using the shortest distance to each non-hydrogen atom
to the smallest (lowest number of heavy atoms) of the
two ligands. It is common for the two ligands in the
comparison to be unique chemical entities with a differ-
ent number of atoms. So, each atom in the smallest
structure is used to calculate the RMSD, while all the
“extra” atoms in the larger structure are ignored. Effec-
tively, the RMSD is measured from the smaller ligand
to an aligned substructure of the larger ligand. The cal-
culated RMSD is then reduced by 0.5 Å to provide a
non-penalty region to accommodate for experimental
error.
CPASS database update
When CPASS was originally developed, a total of
~34,000 X-ray and NMR structures were available from
the RCSB PDB [22]. This led to a CPASS database com-
posed of ~26,000 unique ligand-defined binding sites. A
ligand is broadly defined as any small molecular-weight
organic compound (co-factors, drugs, metabolites, sub-
strates, etc) or small peptide, DNA or RNA strand con-
sisting of thirteen or less residues. A unique ligand-
defined binding site implies that two binding sites that
share the same ligand have less than 90% global
sequence similarity or less than 80% sequence similarity
in the ligand binding site. Common buffers, detergents,
salts and other small ligands are removed from the
CPASS database. Since the original inception, the RCSB
PDB has increased significantly and contains ~68,000 X-
ray and NMR structures as of September 2010. This has
led to a corresponding increase in the CPASS database,
which now comprises ~36,000 unique ligand-defined
binding sites. The resulting increase in the CPASS data-
base improves the coverage of functional space and
increases the likelihood that a match will be found
between a functionally uncharacterized protein and the
CPASS database.
CPASS user interface enhancements
A number of valuable changes to the CPASS user
interface have been incorporated to improve the ease
of use of the program. The CPASS job submission
page has been expanded to include more flexibility in
how a CPASS calculation is performed (Figure 3). In
the original version of CPASS, the user was limited to
the comparison of a single protein target against the
entire CPASS database. The CPASS database could be
reduced to a subset of binding sites by defining a spe-
cific ligand (ATP, PLP, NADP, etc) defined binding
site. These options were expanded in CPASS v.2, a
single pair-wise comparison can be performed against
a user-selected RCSB PDB structure. Similarly, a com-
parison can be calculated using a user-selected list of
RCSB PDB structures. In both cases, the RCSB PDB
structures must contain a bound ligand for a success-
ful CPASS calculation. Also, the user-defined lists can
be further filtered by defining a specific ligand (ATP,
PLP, NADP, etc). Finally, the user can submit two
lists of specific CPASS ligand-binding site files for a
series of pair-wise comparisons. Choosing this option
does not require the user to upload a protein-ligand
structure to CPASS. Instead, the comparison is
strictly between CPASS database files culled from the
RCSB PDB. This requires the user to use the CPASS
file nomenclature for defining a ligand-defined bind-
ing site. A file containing the complete, unfiltered list
of ~100,000 CPASS ligand-defined binding sites is
provided to the user to generate the two lists of spe-
cific CPASS ligand-binding site files for the pair-wise
comparisons.
Furthermore, the original version of CPASS limited
the ligand-defined binding site comparisons to an
experimental protein-ligandc o - s t r u c t u r eu p l o a d e d
by the user, where CPASS extracted the ligand-
defined binding site based on the presence of a
ligand in the uploaded structure. CPASS v.2 allows
the flexibility of a manually defined ligand binding
s i t e ,w h e na ne x p e r i m e n t a lp rotein-ligand co-struc-
ture is not available. The user simply provides a
standard text file listing the residues in the uploaded
protein structure that correspond to the predicted
ligand binding site.
The overall CPASS results table that lists all the
ligand-defined binding sites with a similarity (usually >
30%) to the searched binding site has also been modi-
fied (Figure 4). Specifically, the results table now con-
tains a column that contains a description of the
function associated with each matched ligand-defined
binding site. An additional column was also added that
lists the eggNOG (http://eggnog.embl.de/) functional
classification identification number [32], providing a
direct link to a summary page in our PROtein Func-
tion, Evolution, Structure and Sequence (PROFESS)
database (http://cse.unl.edu/~profess/) [33]. In this
manner, it is now trivial to ascertain if a prevalent
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analysis.
The detailed display of each CPASS aligned ligand-
defined binding-site now includes the ligand structures
(Figure 5). The calculated RMSD between the two
ligands is displayed below the aligned structures. The
program Jmol [34] (http://www.jmol.org/) has replaced
Chime [35] for the graphical display of the overlap of
the two aligned ligand-binding-site structures. Jmol is
a Java-based molecular viewer that is actively being
developed and significantly improves upon the capabil-
ities of Chime. Jmol button options allow for the easy
display of all the residues that define each ligand
defined binding site, the display of only the aligned or
matched residues between the two binding sites, or
selectively turning off the display of either of the two
aligned binding sites. Similarly, Jmol buttons can be
selected to turn on or off residue labels or the ligand
structure. The associated table lists the aligned resi-
dues between the two ligand-defined binding sites, the
Figure 3 An example of a completed CPASS submission page is shown that highlights the enhanced user flexibility in database
selection and search criteria. The queried ligand-defined binding site can be manually or automatically defined. The similarity search can be
conducted against the entire CPASS database, against a single protein structure or against a user defined list of structures. The search can be
further filtered by the type of ligand that defines the ligand binding site. Also, a similarity search can be conducted between two user defined
lists of ligand-defined binding sites present in the CPASS database.
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penalties, and the resulting weighted per residue BLO-
SUM62 score.
Evaluation of CPASS performance
Six different proteins were evaluated using CPASS: gly-
cine hydroxymethyltransferase (PDB: 1 kkp, E.C.
2.1.2.1); aspartate transaminase (PDB: 1yaa, E.C.
2.6.1.1); pyruvate kinase (PDB: 3hqo, E.C. 2.7.1.40);
phosphoenolpyruvate carboxykinase (PDB: 1xkv,
E.C. 4.1.1.49); glutamine-tRNA ligase (PDB: 1gtr, E.C.
6.1.1.18); and biotin carboxylase (PDB: 1dv2, E.C.
6.3.4.14). The ATP or pyridoxal-5’-phosphate (PLP)
ligand binding site from each protein structure was
compared against the entire CPASS database of
~36,000 ligand-defined binding sites. Each of these
Figure 4 An illustration of an overall CPASS results table that lists the reference (queried) CPASS score, the comparison CPASS score,
the percent similarity between the two CPASS scores, and the CPASS IDs for the reference and comparison ligand-defined binding
sites. A functional description and a link to the corresponding PROFESS [25] page for each comparison protein is also provided. The CPASS ID
(highlighted) for the comparison ligand-defined binding site is a link to a detailed description of the specific ligand-binding site alignment (see
Figure 5).
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CPASS search parameters. A default CPASS search uti-
lizes a ligand-defined binding site from an experimen-
tal NMR or X-ray co-structure with the additions to
the similarity function of the ligand RMSD, solvent
accessible surface area, and the Cb position within the
distance calculation. The two other searches either
excluded the ligand RMSD, Cb in the RMSD calcula-
tion, and solvent accessible surface area from the simi-
larity function or used a manually-defined ligand
binding site.
Three different methods were used to define what
constitutes a functionally similar active site (true posi-
tive). The first method only used proteins that were
assigned to the same Enzyme Commission (E.C.) classi-
fication [36] (i.e., all four E.C. numbers are identical),
where the ligand-defined binding sites contained either
the same ligand or a very similar ligand. The second
method simply used a broader definition of E.C. similar-
ity (i.e., only the first three E.C. numbers are required to
be identical). The third method used a very broad defi-
nition of functional homology by defining all active sites
Figure 5 A CPASS alignment summary page is shown that provides a detailed description of the specific ligand-binding site
alignment. An interactive Jmol [26] representation of the two aligned ligand defined active sites determined by CPASS is displayed. The RMSD
between the two ligands, the protein name and ligand name for the comparison ligand-defined binding site are also provided. The associated
table identifies the aligned residues and the per residue ΔRMSDi,j and ΔSASAi,j penalties, and the resulting weighted per residue BLOSUM62 score.
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tionally similar. ROC curves were generated using the
three different definitions of a true positive. The true
positive rates were plotted against false positive rates
over the full range of CPASS similarity scores using the
different CPASS search parameters and the different
definitions of true positives. Similarly, distribution
curves plot the fraction of negatives and the fraction of
positives at each CPASS similarity score using a bin size
of 10. The fraction simply corresponds to the number of
positives or negatives per bin relative to the total
number of positives of negatives. The area under each
curve is 1.
Results
Improvement in CPASS search speed
A notable limitation in the original implementation of
CPASS was the significant time required to complete a
search against the entire CPASS database. On average, a
single comparison took ~40 s, requiring ~24 hrs to
complete a search on our 16-node Beowulf Linux clus-
ter. Obviously, the search time increased proportionally
with the growth in the RCSB PDB database and the
resulting CPASS database. This necessitated strict con-
trol over user access to prevent overwhelming our
laboratory computer resources. In the recent upgrade,
the CPASS code has been optimized, reducing a single
comparison to ~7 s, which is greater than 5-fold
improvement. CPASS has also been further modified to
take advantage of resources available on the Open
Science Grid. As a result, the CPASS calculation time
has been reduced to less than an hour (including set-up
time), more than an order of magnitude improvement.
Importantly, this significant reduction in the CPASS
search time enabled us to remove any user restrictions
to routine access to CPASS. Furthermore, the dramatic
improvement in speed is expected to greatly improve
the wide-spread utilization of CPASS. CPASS is freely
accessible to academic users through our web-site
(http://cpass.unl.edu).
CPASS similarity function
The overall philosophy behind the development of the
CPASS database and program is the application of
experimental ligand-defined binding sites to infer a
functional annotation when global sequence and struc-
ture similarity is inconclusive. In this manner, CPASS
attempts to quantify the structural and sequence simi-
larity between two ligand defined binding sites by spa-
tially overlaying similar residue types. CPASS was
primarily designed to compare experimental ligand-
defined binding sites. Unfortunately, a protein-ligand
co-structure is not always available, but in some cases
the identity of the ligand-binding site may be inferred
from other sources, such as site-directed mutagenesis,
NMR chemical shift perturbations, bioinformatics, or
computer modeling.
The new version of CPASS allows for the manual
identification of the ligand binding site in addition to
the typical extraction of the ligand-binding site from
an uploaded protein-ligand PDB file. The manual defi-
nition of the ligand-binding site simply requires
uploading a standard text file to CPASS. The text file
should list the three letter amino acid abbreviation for
each residue in the binding site, and the corresponding
residue number and chain identifier. The information
should exactly match the corresponding residue identi-
fiers in the protein PDB file that is also uploaded to
CPASS. The use of a manually-defined ligand-binding
site also requires a subtle change in the CPASS simi-
larity function (see eqn. 2), since the structure does
not contain a bound ligand. First, the aligned ligand
RMSD penalty function is disabled. Second, the ratio
o ft h es h o r t e s td i s t a n c et ot h el i g a n d( dmin)a m o n ga l l
amino-acids in the active site compared to each
amino-acid’s shortest distance to the ligand (di)
requires a new reference point since the ligand is not
present. The ligand reference point is simply replaced
by the center-of-mass for the manually defined binding
site. This scaling factor simply reduces the contribu-
tion of residues at the 6 Å edge for inclusion in the
ligand binding site definition. It diminishes the impact
of small structural variations that may result in either
the inclusion or exclusion of residues at the 6 Å limit
that would correlate to an unjustified large difference
in the CPASS similarity score.
CPASS uses a distance-weighted BLOSUM62 scoring
function (see eqn. 2) to align and rank ligand-defined
binding sites. The alignment ignores sequential con-
nectivity and primarily focuses on the relative spatial
orientations of the residues that comprise each binding
site. Importantly, the identity or conformation of the
ligand is not used in this alignment process. To further
improve the ability of the CPASS similarity functions
to eliminate dissimilar ligand-binding sites, three addi-
tions to the CPASS scoring function have been
implemented.
CPASS uses the bound ligands to define the binding
sites or functional epitopes, but the ligands are not used
in the alignment process. This provides an additional
mechanism to evaluate and rank the aligned ligand-
binding sites, since the same transformation that was
applied to align the binding sites are equally applied to
each ligand. Thus, a binding site alignment that also
results in a close alignment between the two bound
ligands, especially if similar functional groups overlap,
increases the likelihood that the two aligned proteins
share a common function. The ligand alignment
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ally apply an increasing penalty as the RMSD between
the two ligands increases; reaching a value of zero when
the ligands are separated by > 4.5 Å (Figure 2A). The
ligand alignment function does not provide a penalty
when the aligned ligands are within 0.5 Å. This com-
pensates for the typical experimental error encountered
when comparing similar protein structures. A conserva-
tive function is applied since the ligand alignment is a
global parameter that simply scales the CPASS similarity
score. A large penalty based on a poor ligand alignment
effectively defines the two ligand-binding sites as dissim-
ilar regardless of how well the ligand-binding sites are
aligned. CPASS also provides an option to exclude the
ligand alignment function from the overall similarity
score.
The original CPASS spatial alignment of ligand bind-
ing sites was based on Ca distances. This clearly cap-
tures the backbone orientations, which is the primary
structural factor that determines ligand-binding site
similarities, but it does ignore subtle and potentially
important differences in side chain orientations. This
issue was reduced by also including Cb distances in the
per residue distance alignment (ΔRMSDi,j) calculation in
the new version of CPASS, requiring a corresponding
upgrade to the CPASS database file structure. Of course,
only Ca distances are used for alignments involving a
glycine. The per-residue distance alignment function
(Figure 2B) does not provide a penalty when the aligned
residues are within 1 Å. This compensates for the typi-
cal experimental error encountered when comparing
similar protein structures. But, the function decays
rapidly as the RMSD increases beyond 1 Å, where a
residue’s alignment makes an insignificant contribution
to the overall similarity score when the RMSD is greater
than 2.5 Å. A relatively harsh per-residue penalty is war-
ranted since the overall similarity score is based on the
sum of all the aligned residues. Basically, two ligand
binding sites that share an average per residue RMSD of
greater than 2.5 Å are not very similar. As a compari-
son, consider the fact that highly similar protein struc-
tures have a global RMSD of less than 2.5 Å [37].
The per-residue solvent accessible surface area
(SASA) captures a distinct physical descriptor that is
unique from both the residue identity and the dis-
tances between aligned residues and bound ligands.
Presumably, the overall characteristics of functionally
related ligand binding sites, including SASA, should be
preserved. Specifically, a shallow ligand binding cleft
on the protein’s surface is distinct from a ligand bind-
ing pocket formed at the interface of two proteins or
domains, or from a deep-binding pocket where a
majority of the binding site residues are buried below
the protein’s surface. Dissimilarity in SASA would
further discriminate between these ligand binding sites
even if there is a serendipitous spatial overlap in a
sub-set of residues. The SASA function (Figure 2C)
was empirically designed to emphasize the penalty for
large SASA differences (≥60) that primarily distin-
guishes between surface accessible and buried residues.
Similar to the ligand alignment function, the user also
has the option to exclude the SASA difference in the
CPASS similarity score.
The various CPASS similarity functions were empiri-
cally designed to proportionally emphasize the contribu-
tions of residue identity, per residue alignment, SASA
and ligand alignment to the overall sequence and struc-
tural similarity between two ligand binding sites. Thus,
the CPASS similarity score that indicates two ligand
binding sites are similar is also empirically evaluated. In
general, CPASS similarities score greater than 30% sug-
gests a moderate level of similarity between two ligand
binding sites. The quality and the confidence in the
ligand-binding site similarity increase with the CPASS
similarity score. This point is easily illustrated by the
comparison between the aspartate aminotransferase pro-
tein (PDB ID 1art) PLP binding site with four different
PLP-dependent proteins, where the CPASS similarity
score decreases from ~80% to ~30% (Figure 6).
Evaluation of CPASS performance
The definition of a true positive is essential to the eva-
luation of CPASS performance. Ideally, a measurement
of functional similarity would provide the necessary fra-
mework to define a true positive, but functional homol-
ogy is still extremely challenging to quantitate [38].
There are several methods for functional classifications
based on sequence similarity (COG [39], eggNOG [40],
OMA [41]), structure similarity (CATH [42], SCOP
[43]), or annotations (Gene Ontology, GO). Unfortu-
nately, there are significant errors associated with each
approach. GO terms are generally reliable and are the
current “gold standard”, but the annotations are often
incomplete and overly generic. Functional clustering
using sequence similaritym a yb et o oc o a r s e( C O G ) ,
which results in the inclusion of paralogs [39,44]; or too
fine (eggNOG, OMA), which results in multiple clusters
with the same function [45]. Of course, there are
numerous examples of proteins that share the same
function, but exhibit minimal sequence similarity
[46,47]. Alternatively, functional divergence increases
significantly as sequence identity drops below 50% [48].
Similar issues arise with structure similarities; there are
proteins that exhibit the same function but have differ-
ent structures, as well as the reverse [49-51]. Thus, the
Enzyme Commission (E.C.) number was the best
approach to define the functional similarity between the
six query proteins and proteins within the CPASS
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enzyme-catalyzed reactions, which provides a generally
reliable, but limited, mechanism to infer homologous
functions.
Receiver operating characteristics (ROC) curves for
two representative CPASS calculations of the proteins,
aspartate transaminase (PDB: 1yaa, E.C. 2.6.1.1) and
glutamine-tRNA ligase (PDB: 1gtr, E.C. 6.1.1.18) are
shown in figure 7A,B. The ROC curves illustrate the
overall ability of CPASS to identify true positives relative
to false positives. The straight-line in the graph indicates
the expected results if the CPASS predictions were com-
pletely random. The performance improves as the curve
moves to the upper-left. As apparent in figure 7A,B, the
enrichment in the ROC curves and the corresponding
improvement in CPASS performance follows the
Figure 6 Illustrations of CPASS similarity scores using a representative aspartate aminotransferase protein (PDB ID 1art) and four
different pyridoxal-5’-phosphate (PLP) dependent proteins: (a) aspartate aminotransferase (PDB ID 1asf) with a CPASS similarity of
82.73%, (b) LL-diaminopimelate aminotransferase (PDB ID 3ei8) with a CPASS similarity of 50.09%, (c) histidinol-phosphate
aminotransferase (PDB ID 1gew) with a CPASS similarity of 42.13%, and (d) cysteine sulfinic acid decarboxylase (PDB ID 2jis) with a
CPASS similarity of 30.85%, at the low end of the confidence limit for a functional relationship. The ligand defined binding sites are
shown as licorice bonds where the molecular graphics images were produced using the UCSF Chimera (http://www.cgl.ucsf.edu/chimera)
package from the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco [52]. The aspartate
aminotransferase protein (PDB ID 1art) is colored blue in each panel, with PLP colored light blue. The other four PLP-dependent proteins in the
binding site comparisons are colored red and the bound PLP is colored orange.
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true positives. The ROC curve where true positives are
based on identical E.C. numbers is essentially ideal. The
ROC curve based on a broader E.C. similarity (only the
first three numbers are identical) is, as expected,
reduced relative to the ROC curve based on identical E.
C. numbers. But, this still shows an improvement over
the ROC curve using true positives based only on pro-
teins binding the same ligand. These results are not sur-
prising. An increase in the accuracy of defining a
functional similarity minimizes the number of proteins
with low CPASS scores that are incorrectly character-
ized as true positives. It is important to note that in all
cases the number of true positives based on identical E.
C. numbers for each of the six query proteins is extre-
mely small (2-28) relative to the size of the CPASS
library (~36,000). This occurs because the CPASS library
has been purposively filtered to remove identical or
highly similar ligand-binding sites. The high CPASS
performance is also illustrated by the distribution of the
true positives and true negatives as a function of CPASS
scores. The CPASS analysis of aspartate transaminase
(Figure 7C) and glutamine-tRNA ligase (Figure 7D) indi-
cate that true negatives peak at a CPASS score of ~10%.
Conversely, true positives have a range of CPASS scores,
but a threshold of ~20-30% is expected to identify the
majority of functionally homologous proteins, while
nearly eliminating false positives. Similar results were
obtained for all six query proteins.
The impact on CPASS performance by the addition
of ligand RMSD, Cb in the RMSD calculation, and
SASA to the similarity function was also evaluated.
Similarly, the manual definition of a ligand binding site
was compared to the experimental definition of a
ligand binding site from an NMR or X-ray structure.
The default CPASS approach uses the ligand of a
protein-ligand co-structure to define the ligand binding
site. As previously discussed, the default definition of a
Figure 7 ROC curves showing the true positive rate relative to the false positive rate of CPASS calculations for (A) aspartate
transaminases (EC 2.6.1.1) and (B) glutamine-tRNA ligases (EC 6.1.1.18). True positives are defined based on three levels of functional
homology between the query protein and the CPASS database. ROC curve with true positives based on an exact EC classification (all four E.C.
numbers are identical) is colored blue. ROC curve with true positives based on a broad EC classification (only first three E.C. numbers are
identical) is colored red. ROC curve with true positives based simply on proteins binding the same ligand is colored green. Distribution curves
showing the fraction of negatives (red) and positives (blue) as a function of CPASS similarity scores (bin size of 10) are shown for (C) aspartate
transaminases (EC 2.6.1.1) and (D) glutamine-tRNA ligases (EC 6.1.1.18).
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in the CPASS similarity score, where residues further
from the ligand contribute less to the overall score
(see eqn. 2). Since a manually defined ligand binding
site lacks a ligand, the scaling factor uses distances
from the center-of-mass for the manually defined
binding site. A ROC curve analysis comparing the
ligand-defined and manually-defined binding sites for
a CPASS calculation with aspartate transaminase
shows no significant difference in CPASS perfor-
mance (data not shown). A similar result was
obtained when comparing a CPASS calculation with
or without the inclusion of Cb in the RMSD calcula-
tion, ligand RMSD and SASA in the CPASS similarity
function. Again, similar results were obtained for all
six query proteins.
The similar performance using a manually-defined
binding site demonstrates the relative robustness of
the CPASS method. This is also evident by the clear
distinction between true positives and true negatives
seen in figure 7C,D. Nevertheless, the ROC curves do
not capture the subtle differences in the CPASS results
caused by using a manually-defined binding site. Figure
8A illustrates a typical distribution in CPASS similarity
scores. The relative separation between the maximal
peaks for negatives and positives is diminished for the
manually-defined binding site. The CPASS scores for
negatives increase and the scores for positives
decrease, resulting in an increase in the overlap at the
typical 20-30% threshold. Also, there is a wider range
in the CPASS similarity scores for the positives.
Despite these changes in the CPASS score distribution,
Figure 8 Representative distribution curves showing the fraction of negatives and positives as a function of CPASS similarity scores
for aspartate transaminases (PDB: 1yaa, EC 2.6.1.1). (A) A comparison of negatives (red) and positives (blue) CPASS similarity score
distributions using a ligand-defined binding site (solid) and a manually-defined binding site (dashed). (B) A comparison of the fraction of
negatives (red) and positives (blue) over the range of similarity scores for CPASS v.2, which includes the addition of Cb in the RMSD calculation,
ligand RMSD, and solvent accessible surface area (solid) to the original implementation of CPASS that lack these features (dashed). (C) A
comparison of the fraction of negatives over the range of similarity scores for CPASS v.2 with all features (solid blue), CPASS v.2 without the
addition of Cb in the RMSD calculation (dashed red), CPASS v.2 without ligand RMSD and solvent accessible surface area (dotted purple), and
CPASS v.1 (dash-dot green).
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t h er a t eo fi d e n t i f y i n gt r u epositives relative to false
positives is maintained. Thus, a manually-defined bind-
ing site still provides very reliable CPASS results, but
t h ed i f f e r e n c ei ns i m i l a r i t ys c o r e sb e t w e e np o s i t i v e s
and negatives is diminished relative to a ligand-defined
binding site.
Similarly, the lack of an apparent improvement in
the ROC curves by the inclusion of the ligand RMSD,
the Cb in the RMSD calculation, and SASA in the
CPASS similarity function is not surprising given the
nearly ideal performance of CPASS seen in figure 7A,
B. Instead, the new CPASS similarity function was pri-
marily expected to reduce the similarity score for nega-
tives, while leaving positive scores unaffected.
Effectively, the improvements to the CPASS similarity
function were anticipated to enhance the differentia-
tion between positives and negatives. A representative
distribution of CPASS similarity scores comparing
CPASS v.1 and CPASS v.2 is shown in figure 8B. As
expected, the distribution of positive scores is basically
unchanged. Similar ligand-defined binding sites are
expected to have essentially identical side-chain orien-
tations, per residue solvent accessible surface areas,
and ligand conformations. Conversely, the CPASS
similarity scores decrease for negatives because of an
apparent deviation in these structural parameters. This
is further illustrated in figure 8C by the sequential
decrease in the fraction of negatives with scores above
20% as the new structural features are incrementally
added to the CPASS similarity function. A threshold of
20-30% in the CPASS similarity score is typically used
to identify potential functional homologs. Thus, the
new CPASS similarity function is more efficient at
eliminating false positives near this threshold. This is
potentially very critical for the analysis of uncharacter-
ized proteins, where a higher confidence in identifying
a functional homolog is achieved even with a modest
CPASS similarity score (≥ 30%).
Conclusion
The overall goal of the CPASS database and software is
to identify similar experimentally-determined ligand
binding sites through an exhaustive pair-wise search of
the RCSB PDB. CPASS optimizes the spatial orientation
of similar amino-acids between two ligand-defined bind-
ing sites and ranks the alignment using a collection of
sequence and structural empirical functions. We report
a series of significant upgrades in CPASS v.2 that
includes a dramatic improvement in speed, an expansion
in the CPASS database of ligand defined binding sites,
and modifications to the CPASS similarity scoring func-
tion and user interface.
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